Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.

Montalescot, G; Philippe, F; Ankri, A; Vicaut, E; Bearez, E; Poulard, J E; Carrie, D; Flammang, D; Dutoit, A; Carayon, A; Jardel, C; Chevrot, M; Bastard, J P; Bigonzi, F; Thomas, D

Montalescot, G; Philippe, F; Ankri, A; Vicaut, E; Bearez, E; Poulard, J E; Carrie, D; Flammang, D; Dutoit, A; Carayon, A; Jardel, C; Chevrot, M; Bastard, J P; Bigonzi, F; Thomas, D.

Affiliation

Montalescot G; Department of Cardiology, Pitié-Salpétrière Hospital, Paris, France. gilles.montalescot@psl.ap-hop-paris.fr

Circulation ; 98(4): 294-9, 1998 Jul 28.

Article in En | MEDLINE | ID: mdl-9711933

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Von Willebrand Factor / Enoxaparin / Angina, Unstable / Anticoagulants / Myocardial Infarction Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: Circulation Year: 1998 Document type: Article Affiliation country: Country of publication:

Search on Google

Add to My VHL

XML

PubMed Links